Introduction

Prostate cancer is the most common type of cancer in men in the United States alone, especially for those who are aged 65 and above. Even though there is no clear way to prevent the disease, a healthy lifestyle and regular check-ups could reduce the danger of having prostate cancer and facilitate the process of early detection. Treatments for localised prostate cancer can include the application of either photon or proton beams. Proton beam therapy (PBT) has a distinctive capability that precisely delivers tumour targeting while reducing injury to healthy normal tissues surrounding the tumours.

Therefore, this technique has the potential to be one of the advantageous treatments related to reducing treatment-related side effects. This provides great promise since it leads to better overall health in the individual undergoing treatment. Although PBT possesses these advantages, the high cost and uncertainty about its long-term efficacy have created controversy regarding its role in the treatment of prostate cancer. The mechanism, clinical effectiveness, side effects, and cost considerations of proton therapy for prostate cancer are discussed here.¹

Mechanism of proton therapy

The fundamental distinction between proton therapy and traditional photon-based radiation therapy lies in the physical properties of the proton beam. Protons are positively charged particles that engage with tissues in a way that allows them to release most of their energy at a particular depth. This phenomenon is referred to as the Bragg Peak.

This allows proton beams to concentrate radiation in an area directly around the site of the tumour and thus spare normal tissue surrounding the tumour. On the other hand, photon beams continuously liberate their energy along their path in the tumour and surrounding healthy tissues. Hence, they are more destructive to other tissues leading to more serious and frequent side effects.

This precision is useful in treating prostate cancer as the proximity of the prostate to sensitive areas like the bladder and rectum is a significant challenge. By manipulating the energy and direction of the proton beam, clinicians can conform the radiation dose to the contours of the tumour. This way, there is less risk of side effects such as urinary incontinence and rectal bleeding.

This approach is especially indicated for those patients with other health issues that make them more sensitive to radiation damage or those interested in ensuring the highest quality of life during and after treatment. This often means striking a balance between trying to eliminate the cancer and preserving as good a quality of life as possible for the individual.²

Proton therapy in the treatment of prostate cancer

Proton therapy offers specific advantages for individuals with localised prostate cancer. For those with low to intermediate risk of disease, proton therapy is a non-invasive treatment option that eliminates the risk of surgical complications, including incontinence and impotence. Proton therapy is particularly fitted for tumours located close to sensitive organs such as the bladder and rectum since the precision enables minimising the probability of destroying these sensitive areas.

Candidates for proton therapy generally include patients with localised prostate cancer who are not good candidates for surgery or who would prefer to avoid an invasive procedure. It is not the best treatment for metastatic disease, due to the nature of the delivery of such a beam in a very limited volume. Proton therapy for high-risk prostate patients is considered one of the promising treatments to improve the outcomes of shrinking the tumour and slowing the disease. The application of proton therapy has been generally different depending on the stage of the cancer. 

It could be delivered as a monotherapy for low-risk patients, and in high-risk diseases, its use could become multimodal, with incorporation into hormones or chemotherapy. Hypofractionated proton therapy, which involves administering larger doses of radiation over a shorter period, has emerged as an option; evidence indicates it might be comparable to traditional fractionated therapy and has the potential to minimise treatment duration and lower expenses for certain patients.³

Clinical effectiveness and outcomes

Proton therapy is considered equivalent in achieving cancer control and survival rates in patients with localised prostate cancer. For example, several studies reported a systematic review where there was no significant difference between patients treated with proton therapy and those treated with intensity-modulated radiation therapy in terms of five-year survival rate. It is possible, however, that proton therapy may have an advantage over traditional radiation therapy in minimising specific side effects, particularly those impacting the urinary and bowel systems. This advantage is likely because lower radiation doses are delivered to the bladder and rectum during proton therapy than during traditional forms of radiation therapy.

Preliminary results with proton therapy seemed promising, but studies concerning long-term effectiveness are low. More research needs to be done to confirm the possible benefits of this treatment over others. While early data indicates a decrease in side effects and maintenance of quality of life, further evidence has to be established to make definite conclusions about its efficacy in the long term.³

Side effects, complications and cost

One of the major points of attraction towards proton therapy has to do with the potential of this therapy to reduce all kinds of side effects attributed to the treatment of prostate cancer. This is based on the fact that traditional radiation treatment brings several complications such as urinary incontinence, rectal bleeding, and erectile dysfunction since healthy tissues are exposed to radiation. The precision of proton therapy in targeting the tumour minimises this exposure decreasing the magnitude and frequency of such complications.

Short-term side effects of proton therapy include fatigue, mild symptoms of the urinary system, and temporary changes to bowel habits such as diarrhoea or cramping. Of course, these are not usually as pronounced as the side effects associated with the more traditional forms of radiation therapy. The long-term side effects are still under investigation, but the risk of secondary cancers and persistent bowel or urinary issues appears to be lower compared to photon-based therapies. Since proton therapy has only recently gained favour, its longer-term safety profile has not yet been fully compiled.

The cost of proton therapy significantly impairs the availability and use of this technology. It costs approximately $100 to $250 million to establish a facility to deliver proton therapy, compared to the relatively modest investment needed to establish a facility providing photon radiation. Increasing initial costs lead to higher costs for the treatment, which are to be borne by both the individual and the health system, rendering proton therapy an inaccessible form of cancer management, particularly in states where this kind of facility does not exist.

Proton therapy is 1.5 to 2 times more expensive when insurance regards the cost of delivery of radiation or possible treatment-related complications compared to IMRT. Insurance coverage for proton therapy is variable: many providers require proof of the clinical benefit of proton therapy compared to traditional therapies before approval. Advancements in technology and the creation of compact and economically friendly proton therapy systems can help reduce barriers over time.³

Patient experience and considerations

The majority of patients who undergo proton therapy are treated in outpatient settings. The course of treatment is generally well tolerated, with most patients maintaining their normal activities without interruption during treatment. Recovery after treatment is also often quicker when compared to other, more invasive treatments, such as surgery. Many patients state a high satisfaction rate due to fewer side effects and the quality of life maintained.

Quality of life is a major concern in the treatment of prostate cancer since the majority of patients will survive many years after diagnosis. The potential of proton therapy to minimise side effects associated with urinary and sexual function makes it an attractive option for those patients who aim to maintain quality of life during and after treatment. The reported experiences of the patients also often mentioned minimal disruption to life and how quickly they returned to normal after proton therapy.

Future of proton therapy in the management of prostate cancer

Proton therapy for prostate cancer is thus far headed in a very positive direction, with several further studies taking place to better increase the accuracy of treatment and even decrease costs. Advances in technology, such as pencil-beam scanning, permit even more precise targeting of tumours, potentially improving treatment outcomes and further minimising side effects. Furthermore, smaller, less expensive systems for proton therapy are in development that will enable this technology to be available to a greater variety of patients and healthcare facilities.

Current clinical trials explore the use of proton therapy in combination with other treatments, such as immunotherapy and targeted therapies, to enhance its effectiveness against prostate cancer. With more available data on this treatment option, its role will be widened in the management of prostate cancer to offer more effective but less toxic alternatives to patients.³

Summary

Proton therapy has emerged as a big step ahead in the management of localised prostate cancer, as this modality may be associated with fewer side effects and improved quality of life compared with classic radiation treatments. Further ongoing studies and technological development are needed, keeping in mind costliness and limited availability; disadvantages can be balanced by these improvements, making proton therapy a more feasible option for prostate cancer treatment.